Lori Dockter, PA
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,359 of the $2,632 with a category attached, or 89.6%. Astellas Pharma US Inc accounts for 89.6% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $1,292 and has fallen 95.1% since, to $64 in 2025. Among medical clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $164.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$2K
- AstraZeneca$70
- Exact Sciences$67
- Johnson & Johnson$33
- Sage Therapeutics, LLC$30
- Amgen$24
- plus $49 from 3 others
What the payments were for
- Consulting fees$2,35990%
- Food & beverage$27310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $2,359 |
| AstraZeneca | 1 | $70 |
| Exact Sciences | 4 | $67 |
| Johnson & Johnson | 1 | $33 |
| Sage Therapeutics, LLC | 2 | $30 |
| Amgen | 1 | $24 |
| Novo Nordisk | 1 | $20 |
| Vertex | 1 | $15 |
| Bayer | 1 | $14 |
How this compares
$2,632 in reported general payments places this provider in the 90th percentile of 51 medical providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 81 | $6,217 |
| Ibandronate Sodium | 56 | $1,850 |
| Levothyroxine Sodium | 93 | $1,385 |
| Clobetasol Propionate | 38 | $1,233 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $701 |
| Escitalopram Oxalate | 35 | $551 |
| YuvafemEstradiol | 11 | $509 |
| Potassium Chloride | 13 | $499 |
| Alendronate Sodium | 44 | $394 |
| Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid | 23 | $373 |
| Losartan Potassium | 34 | $264 |
| Rosuvastatin Calcium | 39 | $258 |
| Omeprazole | 18 | $258 |
| Sertraline Hcl | 27 | $253 |
| Fluoxetine Hcl | 13 | $211 |
Paid to pharmacies, not to this prescriber.
Other medical in Minot
- Bryan PhillipsMinot$4K
- Ginger StrandMinot$843
- Lindsey BakerMinot$176
- Shawn ThompsonMinot$81
- Abir OliverMinot$63
- Keri WeickMinot$60
- Christopher SeilMinot$31
- Mariah NathanMinot$15
- Gregory BjorklundFargo$47K
- Kayla OlsonGrand Forks$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.